Skip to content
The Policy VaultThe Policy Vault

CarbagluCareFirst (Caremark)

N-acetylglutamate synthase (NAGS) deficiency

Initial criteria

  • The diagnosis is confirmed by enzymatic, biochemical, or genetic testing
  • The member has elevated plasma ammonia levels at baseline

Reauthorization criteria

  • Member is experiencing benefit from therapy as evidenced by a decrease in ammonia levels from baseline

Approval duration

12 months